Want to see IBRX full AI Analyst Report?
Top Page
ImmunityBio
(NASDAQ:IBRX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$7.00
▼(-1.41% Downside)
Action:Reiterated
Date:08/04/26
The score is primarily held down by weak financial fundamentals—very large ongoing losses, negative equity, and persistent negative free cash flow—despite strong revenue growth and high gross margins. Technicals also remain soft with the stock trading below key moving averages and negative MACD. Offsetting this, corporate events are notably constructive, with new international approvals and a U.S. BCG supply agreement that strengthen commercial opportunity, but they do not yet resolve the near-term financing and profitability risks.
Positive Factors
Commercial traction
Sustained quarter-to-quarter product revenue growth and record net product sales indicate durable physician adoption of ANKTIVA and an increasingly routinized commercial model. Repeated sequential growth supports scalable recurring revenues, improves visibility for commercial investment, and strengthens long-term revenue base for clinical programs.
Negative Factors
Very large net losses
Nearly $1B in trailing losses and sustained negative equity reflect entrenched operating deficits that impair financial flexibility. Over the medium term, persistent large losses raise the risk of asset write-downs, constrict strategic choices, and necessitate meaningful corrective profitability or continued external capital to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction
Sustained quarter-to-quarter product revenue growth and record net product sales indicate durable physician adoption of ANKTIVA and an increasingly routinized commercial model. Repeated sequential growth supports scalable recurring revenues, improves visibility for commercial investment, and strengthens long-term revenue base for clinical programs.
Read all positive factors
ImmunityBio Key Performance Indicators (KPIs)
ImmunityBio (IBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.51B
Dividend YieldN/A
Average Volume (3M)11.35M
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth351.53%
EPS Growth-54.81%
CountryUS
Employees691
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.97
Shares Outstanding1,047,354,000
10 Day Avg. Volume8,016,374
30 Day Avg. Volume11,347,191
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside83.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$222.44M
ImmunityBio Business Overview & Revenue Model
Company Description
ImmunityBio, Inc. (IBRX) is a commercial-stage biotechnology company focused on developing and commercializing immune-based therapies for cancer and infectious diseases. The company’s core portfolio includes cytokine-based and cell-based immunothe...
How the Company Makes Money
ImmunityBio makes money primarily from product revenue generated by selling ANKTIVA in the United States following FDA approval for use in combination with BCG in indicated NMIBC patients. Revenue is recognized based on the company’s commercial di...
ImmunityBio Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call highlighted strong commercial traction for ANKTIVA with very large year-over-year revenue and unit growth, multiple regulatory milestones (including EU conditional authorization and Saudi first-in-world lung cancer approval), robust enrollment and promising clinical signals across randomized and single-arm QUILT programs, and strategic commercial partnerships and manufacturing initiatives. Offsetting these positives are substantial operating losses and cash burn, significant balance sheet liabilities, continued high R&D investment (including a one-time $14M equipment write-off), and some regulatory delays and market-access complexity in certain cohorts and geographies. Overall, the company is demonstrating clear commercial momentum and clinical progress but remains capital-intensive and faces execution and regulatory risks as it scales internationally.Positive Updates
Transformational Revenue Growth for ANKTIVA
Full-year net product revenue for ANKTIVA was $113.0M in FY2025 versus $14.1M in FY2024, a 700% year-over-year increase; unit sales volume increased ~750% year-over-year, and Q4 revenue of $38.3M represented a 20% sequential increase vs Q3, indicating accelerating commercial adoption.
Negative Updates
Large Net Loss and Cash Burn
Net loss was $351.4M in FY2025; net cash used before operating activities was $304.9M for the year while consolidated cash, cash equivalents and marketable securities stood at $242.8M as of Dec 31, 2025, indicating significant near-term cash burn relative to on‑hand liquidity.
Read all updates
Q4-2025 Updates
Positive
Negative
Transformational Revenue Growth for ANKTIVA
Full-year net product revenue for ANKTIVA was $113.0M in FY2025 versus $14.1M in FY2024, a 700% year-over-year increase; unit sales volume increased ~750% year-over-year, and Q4 revenue of $38.3M represented a 20% sequential increase vs Q3, indicating accelerating commercial adoption.
Read all positive updates
Company Guidance
The company did not provide forward financial guidance on the call but gave extensive 2025 metrics and near‑term milestones: ANKTIVA net product revenue was $113.0M in FY2025 (up 700% vs $14.1M in FY2024) with unit volumes +750% YoY and Q4 revenue $38.3M versus Q3 $31.1M (+20% sequential); ANKTIVA is authorized in 33 countries across four major jurisdictions (US, U.K., EU, KSA) with an EU conditional marketing authorization in Feb‑2026 and two Saudi approvals (bladder and conditional NSCLC combo) in Jan‑2026; cash, cash equivalents and marketable securities were $242.8M at 12/31/2025 and net cash used in operations was $304.9M for the year; FY R&D expense was $218.6M (vs $190.2M in 2024), SG&A was $150M (down from $168.8M), and FY net loss attributable to common stockholders was $351.4M (improved from $413.6M); key liabilities include $505M related‑party convertible notes and ~ $325M revenue‑interest liability. Clinical/regulatory metrics highlighted: QUILT‑2.005 fully enrolled 366 patients (interim 6‑month CR 85% vs 57%; 9‑month 84% vs 52%), QUILT‑3.032 Cohort A CR 71% (n≈100) with duration >53 months and Cohort B 12‑month DFS 58% / 24‑month DFS 52% with 36‑month disease‑specific survival 96% and ~82% bladder preservation; recombinant BCG expanded access spans ~100 sites and ~580 patients with several thousand doses delivered, BCG‑naive enrollment reported at 100% with a targeted BLA in Q4‑2026, QUILT‑3.055 treated ~147 patients, and the company introduced its askIB AI platform and NANT Leonardo automated cell‑manufacturing plans.ImmunityBio Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
20
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 165.79M | 113.29M | 14.74M | 622.00K | 240.00K | 934.00K |
| Gross Profit | 156.88M | 112.53M | 14.74M | 622.00K | 240.00K | 934.00K |
| EBITDA | -888.34M | -223.56M | -264.43M | -478.66M | -351.88M | -320.75M |
| Net Income | -992.36M | -351.40M | -413.56M | -583.20M | -416.57M | -346.79M |
Balance Sheet | ||||||
| Total Assets | 628.50M | 501.90M | 382.93M | 504.45M | 362.36M | 468.91M |
| Cash, Cash Equivalents and Short-Term Investments | 357.37M | 242.82M | 149.81M | 266.46M | 107.18M | 317.12M |
| Total Debt | 38.71M | 878.12M | 504.17M | 726.72M | 723.77M | 645.66M |
| Total Liabilities | 1.67B | 1.00B | 871.06M | 1.09B | 812.18M | 712.82M |
| Stockholders Equity | -1.05B | -499.57M | -489.10M | -586.99M | -447.33M | -242.17M |
Cash Flow | ||||||
| Free Cash Flow | -365.63M | -308.78M | -398.12M | -397.34M | -415.67M | -307.98M |
| Operating Cash Flow | -356.50M | -304.94M | -391.24M | -366.76M | -337.51M | -274.42M |
| Investing Cash Flow | -308.56M | -149.80M | -12.25M | -30.47M | 27.30M | -84.89M |
| Financing Cash Flow | 720.71M | 400.24M | 281.63M | 558.34M | 233.61M | 505.44M |
ImmunityBio Technical Analysis
Positive
7.10
Price Trends
7.63
Negative
7.68
Negative
6.01
Positive
Market Momentum
-0.21
Positive
47.10
Neutral
53.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Positive. The current price of 7.1 is below the 20-day moving average (MA) of 7.42, below the 50-day MA of 7.63, and above the 200-day MA of 6.01, indicating a neutral trend. The MACD of -0.21 indicates Positive momentum. The RSI at 47.10 is Neutral, neither overbought nor oversold. The STOCH value of 53.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBRX.
ImmunityBio Risk Analysis
ImmunityBio disclosed 95 risk factors in its most recent earnings report. ImmunityBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ImmunityBio Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.46B | -2.77 | -29.99% | ― | 213.96% | 25.74% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $3.55B | -8.90 | -87.98% | ― | 67.38% | 24.05% | |
52 Neutral | $2.58B | -9.52 | -51.15% | ― | -63.29% | 25.39% | |
48 Neutral | $7.51B | -8.40 | 135.03% | ― | 351.53% | -54.81% | |
48 Neutral | $1.72B | -90.30 | -4.83% | ― | 23.64% | ― | |
47 Neutral | $7.81B | -7.85 | -32.51% | ― | ― | -71.33% |
* General Sector Average
IBRX
ImmunityBio
7.32
4.92
204.37%
RCUS
Arcus Biosciences
28.33
19.05
205.28%
VIR
Vir Biotechnology
8.77
4.42
101.49%
PCVX
Vaxcyte
58.89
28.88
96.23%
IMNM
Immunome
25.82
15.95
161.60%
IMCR
Immunocore Holdings
34.50
2.57
8.05%
ImmunityBio Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ImmunityBio wins UAE approval for ANKTIVA cancer therapies
Positive
Jul 30, 2026
On July 29, 2026, ImmunityBio announced that the Emirates Drug Establishment of the United Arab Emirates granted marketing authorization for ANKTIVA in two indications, expanding the drug’s approvals to 34 countries and marking the broadest ...
Executive/Board ChangesShareholder Meetings
ImmunityBio Shareholders Reelect Board at 2026 Annual Meeting
Positive
Jun 10, 2026
On June 9, 2026, ImmunityBio, Inc. held its 2026 Annual Meeting of Stockholders, with approximately 85% of outstanding common shares represented, establishing a quorum and signaling strong shareholder engagement. At the meeting, stockholders re-el...
Business Operations and StrategyProduct-Related Announcements
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S.
Positive
May 18, 2026
On May 14, 2026, ImmunityBio entered an exclusive 10-year U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strain of Bacillus Calmette-Guérin, granting ImmunityBio sole rights to develop, import, and commercia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.